Vivax Malaria Clinical Trial
— VHXOfficial title:
A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border
Verified date | August 2013 |
Source | University of Oxford |
Contact | n/a |
Is FDA regulated | No |
Health authority | Thailand: Ethical Committee |
Study type | Interventional |
This is a randomised open label trial with follow up for 1 year. 660 adults and children above 6 months diagnosed with acute Plasmodium vivax will be randomised into 3 groups, either chloroquine, artesunate, or chloroquine/primaquine therapy. Participants will be screened on the day of inclusion then followed weekly for 8 visits and every 4 weeks until week 52. The primary objective of the study is to compare the efficacy of the WHO and Thai Ministry of Public Health recommended radical curative regimen of chloroquine and primaquine with the currently used monotherapy regimens of chloroquine and artesunate along the Thai-Burmese border.
Status | Completed |
Enrollment | 655 |
Est. completion date | October 2012 |
Est. primary completion date | October 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Months and older |
Eligibility |
Inclusion Criteria: - Adults and children > 6 months - Weight > 7 kg for children - Have not had primaquine since last Pv episode - Participant (or parent/guardian if < 18 years old) is willing and able to give written informed consent - Microscopic diagnosis of Plasmodium vivax mono-infection - Ability (in the investigators opinion) and willingness of patient or parent/guardian to comply with all study requirements Exclusion Criteria - Allergy to artesunate, chloroquine or primaquine - Severe malaria - Patients with microscopic diagnosis of co-infection with Plasmodium falciparum - Presence of any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study - Inability to tolerate oral medication - Pregnancy - Blood transfusion in the last 3 months - Antimalarial in last 2 months |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Thailand | Shoklo Malaria Research Unit | Mae Sot |
Lead Sponsor | Collaborator |
---|---|
University of Oxford | Mahidol University |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The first recurrence of Plasmodium vivax malaria | The first recurrence of Plasmodium vivax malaria within 28 days | Day 28 | No |
Secondary | Any recurrence of Plasmodium vivax parasitemia | Any recurrence of Plasmodium vivax parasitemia within the follow up period | 1 year | No |
Secondary | Time to first recurrence, median time between episodes of vivax infections and total number of episodes | Time to first recurrence, median time between episodes of vivax infections and total number of episodes in the follow up period | 1 year | No |
Secondary | Overall number of days of illness and haematocrit below 30% | Overall number of days of illness and haematocrit below 30% within the follow up period | 1 year | No |
Secondary | Chloroquine level | Whole blood chloroquine level at day 7 and any day of recurrence of Plasmodium vivax malaria | Day 7 | No |
Secondary | Adverse events | Adverse event profiles of artesunate, chloroquine and primaquine | 1 year | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01625871 -
Artemether/Lumefantrine and Vivax Malaria
|
Phase 3 | |
Completed |
NCT02876549 -
G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria
|
Phase 4 | |
Completed |
NCT01218932 -
Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04228315 -
Biomarkers of P. Vivax Relapse
|
N/A | |
Completed |
NCT02118090 -
Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:
|
Phase 4 | |
Completed |
NCT04222088 -
TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
|
||
Completed |
NCT01546961 -
Chloroquine Population Pharmacokinetics in Pre and Post-partum Women
|
N/A | |
Completed |
NCT00158548 -
ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
|
Phase 3 | |
Completed |
NCT00682578 -
A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
|
Phase 3 | |
Completed |
NCT00157833 -
A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.
|
N/A | |
Active, not recruiting |
NCT03529396 -
Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients
|
Phase 2 | |
Recruiting |
NCT05874271 -
Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea
|
N/A | |
Completed |
NCT05958797 -
TES of Chloroquine for Pv in the Philippines in 2016
|
||
Completed |
NCT01716260 -
Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan
|
N/A | |
Completed |
NCT01288820 -
Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria
|
Phase 3 | |
Completed |
NCT01640574 -
Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)
|
Phase 3 | |
Completed |
NCT01076868 -
Incidence of Vivax Along the Thai Burma Border
|
N/A | |
Completed |
NCT00158561 -
Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria
|
Phase 3 | |
Completed |
NCT01780753 -
Primaquine Pharmacokinetics in Lactating Women and Their Infants
|
Phase 1 | |
Completed |
NCT06044805 -
Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax
|
Phase 4 |